DeutschNewstral
Article
jdsupra.com on 2022-07-12 18:53
Mylan Files New IPR Petitions on Aflibercept Patents
Related news
- Mylan Files Ten Additional IPR Petitions Challenging Sanofi’s Lantus Patentsjdsupra.com
- Mylan Files IPR on Regeneron Aflibercept Patentjdsupra.com
- Celltrion and Samsung File IPR Petitions on Aflibercept Patentsjdsupra.com
- Celltrion Files Petitions for IPR of Three Rituximab Patentsjdsupra.com
- Celltrion Files IPR Petition on Aflibercept Patentjdsupra.com
- Celltrion Files Two Additional Petitions for IPR of Genentech’s Trastuzumab Patentsjdsupra.com
- Fresenius files IPR petitions challenging Chugai/Roche/Genentech rheumatoid arthritis patentsjdsupra.com
- Celltrion Files Two Additional Petitions for IPR on Genentech’s Trastuzumab Patentsjdsupra.com
- Samsung Files IPR Petition on Regeneron’s Aflibercept Patentjdsupra.com
- Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patentjdsupra.com
- Mylan Files Two Petitions for IPR of Sanofi’s Insulin Glargine Patentsjdsupra.com
- Regeneron Identifies Six Patents for Expedited Trial in BPCIA Aflibercept Case Against Mylanjdsupra.com
- Aflibercept IPR Updates - July 2023jdsupra.com
- DOJ Files IPR Petitions Against Discovery Patentsjdsupra.com
- Breaking: Judgment in Regeneron v. Mylan (aflibercept) BPCIA Case Finding Some Claims of Asserted Patents Valid and Infringedjdsupra.com
- Mylan Files Two Petitions for IPR on Genentech’s Herceptin Patentjdsupra.com
- Board Grants Hospira Mixed Results on its Five Petitions for IPR of Genentech’s Trastuzumab Patentsjdsupra.com
- EYLEA® (aflibercept) IPR and BPCIA Litigation Updatesjdsupra.com
- EYLEA® (aflibercept) and Soliris® (eculizumab) IPR Updatesjdsupra.com
- Sandoz Files Petitions for IPR on Two Abbvie Adalimumab Patentsjdsupra.com